Home

Market Sizing — AU/NZ GLP-1 Companion Supplements

Pillar 5 of 9 · 32 sources cited · May 2026

NZ and AU TAM/SAM/SOM built bottom-up, with the $4.2B global figure audited.

Executive Summary

Headline figures: Australia is a $132–$288M opportunity today and a $700M–$2.7B opportunity by 2030 — but the 2030 number is gated entirely on PBS listing of Wegovy, which would expand the active user base from ~500,000 to ~2.5 million Australians. New Zealand is a separate, much smaller market (NZD $7–$15M today) with a step-change catalyst pending: the December 2025 Pharmac provisional HIGH PRIORITY recommendation for Wegovy funding.[5][6][17]

The US$4.2B (2025) → US$8.4B (2030) figure circulated in trade media has no confirmed primary source. The closest verifiable anchor is Future Market Insights (FMI), which publishes US$4.1B (2025) → US$13.0B (2035) at a 12.2% CAGR — a materially different trajectory.[1][11] The $8.4B figure is internally inconsistent: projecting FMI's own $4.1B at their stated 12.2% CAGR over five years yields approximately $7.3B, not $8.4B. Reaching $8.4B by 2030 would require a ~15% CAGR that FMI does not claim.[7][18] The FMI figure itself is Tier-4 credibility — ESOMAR certified but distributed via syndicated press releases with no published methodology — and provides no country-level disaggregation for AU or NZ. Bottom-up construction from prescription volumes × attach rate × ARPU is the appropriate method for AU/NZ investor-grade sizing.

Australia has approximately 490,000–500,000 active GLP-1 users per month as of 2024/25, representing a ~10-fold increase since May 2020 and approximately 2% of the adult population.[14][29] Semaglutide (Ozempic/Wegovy) accounts for 63.3% of units and tirzepatide (Mounjaro) for 30.7%.[14] Critically, 47.8% of all units flow through the private market, with ~180,000–240,000 private-pay weight loss users spending AUD $4,000–$5,000 annually on their medication alone — a cohort with both the health motivation and financial capacity to purchase companion supplements.[14] The medRxiv authors project almost 1 in 10 Australians on a GLP-1 RA by 2030, implying ~2.5–2.6 million active users, the trigger event being PBS listing of Wegovy (PBAC provisionally recommended in January 2026 with criteria: BMI ≥35 + cardiovascular event at ~AUD $25/script).[14][29]

New Zealand's market is at a fundamentally earlier stage. Wegovy became available on prescription only in July 2025, and the entire current weight-loss GLP-1 user base is 18,178 individuals (Te Whatu Ora data) — equivalent to 0.35% of the NZ population and just 1.1% of the estimated 1.68 million obese NZ adults.[25][26] NZ ranks 3rd highest in the OECD for adult obesity at a 33% rate, with NZD $4–9 billion in estimated annual health costs from excess weight.[26] The current private-pay cost of NZD $370–$600/month for Wegovy is the primary access barrier. The December 2025 Pharmac advisory group provisional HIGH PRIORITY recommendation to fund Wegovy (criteria: BMI ≥27 with cardiovascular disease; BMI ≥30 with comorbidity) is the defining catalyst — under even a 5% uptake scenario, an additional 20,000–30,000 patients would be added rapidly once funded, with the potential for 300,000–400,000 eligible users in a fully penetrated market.[17][6]

Clinical demand for companion supplements has a structural floor rooted in GLP-1 pharmacology: 25–39% of total weight lost on GLP-1 therapy is lean mass, with some studies placing the muscle fraction at 40–60% over 36–72 weeks.[4][19] At 6 months, 12.7% of GLP-1 users develop a new nutritional deficiency (vitamin D 7.5%, iron 1.6%), with deficiency rates rising further at 12 months.[19] Up to 50% report GI side effects — nausea, vomiting, diarrhea, or constipation — creating demand for fiber, probiotics, and electrolytes.[32] GLP-1 users also eat an average of 20% less food and spend 31% less at grocery stores, amplifying the nutrient gap that supplements address.[30][15] GLP-1-related product claim launches grew at a 124% CAGR over the past five years (Innova Market Insights), with North America capturing 83% of that activity — AU/NZ are early in this curve with the same clinical fundamentals.[15]

Working attach rate assumptions for the AU/NZ bottom-up models are anchored to US Acosta Group consumer survey data showing ~30% of GLP-1 users purchase protein shakes, protein powders, and protein bars.[4][19] The conservative scenario uses 25–30% (protein-only, early market); the mid-case uses 30–40% (protein + fiber/probiotic); the 2030 optimistic scenario uses 40–60% (mature market with clinical integration routine).[15] No published AU/NZ-specific attach rate data exists — these US proxies are the best available inputs. Monthly ARPU benchmarks range from AUD $50–$75 (protein + basic multivitamin) to AUD $100–$150 (protein + fiber + multivitamin bundle) to AUD $200–$300 for premium programs with coaching.[9][30] The private-pay sub-segment alone — at 40% attach and AUD $150/month ARPU — generates a SAM of approximately AUD $130–$170M annually from the most commercially valuable cohort.

The broader AU supplement market provides triangulation that validates these estimates. Grand View Research sizes the AU weight loss supplements market at USD $882M (AUD ~$1.35B) in 2024 with a 14.9% CAGR through 2030.[8] The GLP-1 companion sub-segment at AUD $132–$220M in 2025 represents approximately 10–16% of this parent category — internally consistent with an early-stage, fast-growing sub-segment. AU+NZ combined dietary supplements (Grand View Research) total USD $3.96B (2025) growing at 10.6% CAGR, with proteins and amino acids the fastest-growing sub-segment at 13.9% CAGR.[12] NZ's per-capita VMS spend is only 47% of Australia's (USD $24.93 vs. USD $52.52), reflecting a less mature supplement culture that further discounts near-term NZ expectations relative to AU.[20][21]

Market Current TAM (2025) 2030 TAM — Mid-Case Key Catalyst
Australia[5][9][22] AUD $132–$288M AUD $700M–$1.2B PBS Wegovy listing (PBAC recommendation Jan 2026)
New Zealand[6][17][25] NZD $7–$15M NZD $54–$81M Pharmac Wegovy funding approval (in price negotiation)
AU+NZ Combined[22] AUD $140–$305M AUD $750M–$1.3B Both PBS + Pharmac listing events required

For market entrants, the strategic read is straightforward: the AU market is real and material today (AUD $132–$220M at conservative assumptions), driven by 180,000–240,000 private-pay weight loss users with demonstrated willingness to spend. The strategically optimal entry cohort is private-pay, not PBS-funded — these users already spend AUD $4,000–$5,000 annually on medication and are 3–4× more likely to pay premium ARPU for companion supplements than future PBS patients subsidised at AUD $25/script. A DTC brand targeting this sub-segment exclusively can build to AUD $10–$20M revenue with modest share, before PBS listing creates the larger but lower-ARPU mass-market wave. NZ requires patience: the current NZD $7–$15M TAM supports only a single well-positioned entrant, but the Pharmac funding decision — if approved under BMI ≥30 criteria — would create a 3–4× expansion in 24–36 months, making a pre-funding market entry the correct timing for a brand that needs 12–18 months to establish clinical credibility and distribution.

Table of Contents

  1. Global "$4.2B → $8.4B" Claim: Source Interrogation & Credibility
  2. The FMI $4.1B Figure: Methodology, Segments & Credibility Assessment
  3. CAGR Comparison Across Market Research Firms
  4. Australia: GLP-1 Prescription Volume & Active User Base
  5. New Zealand: GLP-1 Prescription Volume & Regulatory Status
  6. Australia: Obesity Prevalence & Clinically Addressable Population
  7. New Zealand: Obesity Prevalence & Market Context
  8. Australia: Broader Weight Management & Supplement Market (Triangulation Anchors)
  9. AU+NZ Combined Dietary Supplements Market
  10. GLP-1 Supplement Attach Rates & Clinical Demand Drivers
  11. ARPU & Spending Dynamics
  12. Bottom-Up Sizing: New Zealand TAM / SAM / SOM
  13. Bottom-Up Sizing: Australia TAM / SAM / SOM
  14. Emerging Product Categories, Innovation & Brand Activity
  15. Data Quality Scorecard & Discrepancy Register

Section 1: Global "$4.2B → $8.4B" Claim — Source Interrogation & Credibility

The figure combination "USD $4.2 billion (2025) → USD $8.4 billion by 2030" for the global GLP-1 nutritional support supplement market is widely circulated in trade media but cannot be traced to any verifiable primary source in publicly indexed market research.[18][7] The nearest confirmed primary source is Future Market Insights (FMI), which reports USD $4.1 billion (2025) → USD $13 billion (2035) at a 12.2% CAGR — a materially different trajectory from the "$8.4B by 2030" version in circulation.[1][11][23]

Key finding: The "$8.4B by 2030" figure is mathematically inconsistent with FMI's own data. Projecting FMI's $4.1B at their stated 12.2% CAGR over five years yields approximately $7.3B — not $8.4B. Reaching $8.4B in 2030 would require a ~15% CAGR, which FMI does not claim. No confirmed primary source for the $8.4B figure has been identified.[7][18]

Competing Global Market Figures — What Sources Actually Publish

Source Category Defined 2025 Market Size (USD) End Forecast CAGR Credibility Note
Future Market Insights (FMI)[1][11] GLP-1 Nutritional Support Supplements $4.1B $13.0B (2035) 12.2% ESOMAR certified; full methodology paywalled
marketintelo.com[18] GLP-1 food/beverage impact (broader scope) $4.6B — 18.2% Low credibility; no methodology disclosed
researchintelo.com[18] GLP-1 consumer food/retail (broadest scope) $14.2B $39.8B (2034) 12.4% Very low credibility; scope inflation likely
Widely cited in trade media[18] Unspecified "GLP-1 supplements" $4.2B $8.4B (2030) ~15% implied No confirmed primary source identified

Probable Origins of the $4.2B / $8.4B Figures

  1. Rounding of FMI's $4.1B — most likely explanation for the "$4.2B" figure[18]
  2. A paywalled primary report not publicly indexed, with different assumptions than FMI's published summary[7]
  3. Secondary aggregation by a trade or blog outlet blending multiple firm estimates without attribution[18]
  4. An earlier or revised FMI report using different base year or forecast horizon assumptions[1]

Decision rule for this analysis: The FMI $4.1B / 12.2% CAGR figure is the only publicly verifiable global anchor. It is treated as a directional order-of-magnitude estimate only. Bottom-up construction from AU/NZ prescription volumes × attach rate × ARPU is the primary analytical method for investor-grade sizing.[18][7]

Section 2: The FMI $4.1B Figure — Methodology, Segment Data & Credibility

Future Market Insights (FMI) is the confirmed source of the consensus global GLP-1 nutritional support supplement market estimate. The firm's "GLP-1 Nutritional Support Market Size & Share 2025–2035" report covers 40+ countries across 8 regions, with AU/NZ grouped under "South Asia & Pacific" — no country-level disaggregation is published in the public summary.[1][11][23]

Published Segment Data (FMI, 2025)

Dimension Leading Segment Share / Metric
Product type[11] Protein & Macronutrient Blends 43% market share (2025; up from 39.4% in 2024)
Dosage form[1] Powders 38% of dosage form segment
Distribution channel[11] Prescription (Rx) 72% revenue share
Primary demographic[23] Ages 35–54 33% share
DTC subscription growth[11] Direct-to-consumer powder subscriptions +18.2% in 2025
Market contribution[11] Share of GLP-1 pharmaceutical ecosystem 3–5%

FMI Methodology Assessment

Dimension Assessment
Firm tier Lower-tier commercial research firm; no AU/NZ country-level precision comparable to Euromonitor, Mintel, or IBISWorld in their published outputs for this region
Methodology disclosure[7] Top-down + bottom-up; Porter's Five Forces + PESTLE; primary interviews; all detail paywalled
Category definition[18] Unclear — "GLP-1 nutritional support" may conflate prescription companion supplements with OTC GLP-1-mimicking products (e.g., berberine)
Distribution channel[7] Majority of public summary appears via OpenPR syndicated press releases — no independent validation
Certification[18] ESOMAR certified (positive signal, but certification does not validate specific figures)
Corroborating signals[15] Consistent with industry activity: Nestlé, Herbalife, Vitamin Shoppe, ADM, FrieslandCampina all making substantive GLP-1 companion investments
Bottom line[18] Use as directional order-of-magnitude only; AU/NZ-specific figures must be bottom-up derived
Key finding: FMI's global figure of $4.1B (2025) implies the AU+NZ combined companion supplement market is a small fraction — roughly $15–40M USD annually at a population-weighted share — but FMI publishes no country-level data for AU or NZ, making the global figure of limited direct utility.[1][11]

Section 3: CAGR Comparison Across Market Research Firms

Multiple firms publish CAGR estimates for adjacent market segments that serve as range anchors for the AU/NZ companion supplement market growth trajectory. A critical misattribution has propagated through trade media: Grand View Research's 14.9% CAGR figure refers to the Australia weight loss supplements market, not the global GLP-1 companion supplement market — these are distinct categories.[7][18][8]

Source Market Segment CAGR Period Geographic Scope
Future Market Insights[1] GLP-1 Nutritional Support (supplements) 12.2% 2025–2035 Global
Grand View Research[8] Weight Loss Supplements 14.9% 2025–2030 Australia only
Grand View Research[12] Dietary Supplements 10.6% 2025–2030 AU+NZ combined
Grand View Research[3] Nutraceuticals (broader — incl. food & beverage) 9.5% 2025–2033 AU+NZ combined
IMARC Group[10] Dietary Supplements 7.02% 2026–2034 Australia only
Mordor Intelligence[10] Dietary Supplements 8.33% 2025–2030 Australia only
Precedence Research[27] Protein Supplements 6.72% 2026–2034 Australia only
Statista[20] Vitamins & Minerals 6.41% 2024–2029 Australia only
Statista[21] Vitamins & Minerals 6.33% 2024–2029 New Zealand only
Grand View Research[12] Proteins & amino acids sub-segment 13.9% 2025–2030 AU+NZ combined
NutraIngredients (functional drinks)[28] GLP-1-friendly functional drinks 12.8% 2025–2033 Global
Fortune Business Insights[7] GLP-1 Receptor Agonist (pharmaceutical drug market) 16.80% 2026–2034 Global

See also: Competitive Landscape for brand-specific growth rates; GLP-1 Adoption NZ/AU for prescription volume growth drivers.

Key finding: For the AU GLP-1 companion supplement category specifically, 14.9% CAGR (Grand View Research's AU weight loss supplements figure) is the most applicable peer benchmark — it covers the broadest relevant AU supplement category and aligns directionally with the protein & amino acids sub-segment CAGR of 13.9%.[8][12]

Section 4: Australia — GLP-1 Prescription Volume & Active User Base

The primary source for AU GLP-1 prescription volume is a medRxiv preprint — "The GLP-1 RA Boom: Trends in Publicly Subsidised and Private Access in Australia, 2020–2025" — based on national pharmaceutical sales data and PBS dispensing claims. The study is not yet peer-reviewed.[14][5] An independent estimate from UNSW research, cited by PBS.gov.au, corroborates the headline figure: "nearly 500,000 Australians (~2% of adult population) using GLP-1 drugs."[29]

Current User Base (May 2024 – April 2025)

Metric Value Source
Total GLP-1 RA sales growth since May 2020 ~10-fold increase [14][5]
Monthly units sold (2024/25) ~500,000 units/month [14]
Total units sold (May 2024–Apr 2025) Over 6 million units [5]
Active GLP-1 users per month (estimated) 482,788 – 501,907 Australians [14]
As % of total population ~1.8% on standard maintenance dose per day [14]
Independent corroboration (UNSW/PBS) ~2% of adult population [29]

Product Mix & Access Channel (May 2024–Apr 2025)

Segment Share of Units Notes
Semaglutide (Ozempic/Wegovy)[14] 63.3% PBS-funded for T2D; private for weight loss
Tirzepatide (Mounjaro)[14] 30.7% 100% private access — no PBS listing
All units via private market (not PBS)[14] 47.8% ~240,000 private-pay users/month
Semaglutide via private access[14] 26.9% of semaglutide Weight loss indication primarily
Tirzepatide via private access[14] 100% of tirzepatide Not PBS listed; AUD $345–$645/month

Private-Pay Weight Loss Users (Primary Supplement Buyer Segment)

Private-pay GLP-1 users — predominantly purchasing for weight loss — represent the most commercially significant segment for companion supplement attach. These users are: paying AUD $4,000–$5,000 annually out-of-pocket for their GLP-1 medication, health-motivated, and highly intentional consumers.[14][29]

Access Segment Estimated Monthly Users Annual Drug Cost (AUD)
Private-pay weight loss GLP-1[14] 180,018 – 239,725 $4,000–$5,000
PBS-subsidised T2D GLP-1[14] ~260,000–310,000 ~AUD $42/month (Ozempic)
Total active AU GLP-1 users[14][29] ~490,000–500,000 Blended

Key Regulatory Events Timeline (AU)

Date Event
May 2020[14] Start of medRxiv study period; GLP-1 RA tracking commences
August 2024[14] Wegovy launched in Australia
September 2024[13] Mounjaro (tirzepatide) TGA approved for weight management
October 2024[29] Compounded GLP-1 replicas banned
December 2024[13] Wegovy TGA approved for cardiovascular indication
December 2025[14] Saxenda discontinued in Australia
January 2026[29] PBAC recommended PBS listing of Wegovy (BMI ≥35 + cardiovascular event; ~AUD $25/script)

2030 AU User Base Projection

The medRxiv authors project almost 1 in 10 Australians on a GLP-1 RA by 2030, implying ~2.5–2.6 million active users.[14][5] PBS listing of Wegovy (pending as of January 2026, criteria: BMI ≥35 + cardiovascular event) is the primary catalytic variable — if criteria broaden at listing, uptake could accelerate significantly beyond the private-payer base.[29]

Section 5: New Zealand — GLP-1 Prescription Volume & Regulatory Status

New Zealand's GLP-1 landscape is at an earlier stage than Australia's, defined by the absence of Pharmac (public) funding for weight-loss GLP-1s and a private-pay market that launched only in July 2025 with Wegovy. The December 2025 provisional Pharmac funding recommendation is the key market-defining event for NZ companion supplement TAM expansion.[17][6][25]

NZ Regulatory Timeline

Date Event
2023[17] Medsafe approved Ozempic for type 2 diabetes in NZ
December 2023[17] PHARMAC restricted funded access to existing users only (supply crisis)
1 May 2024[17] No new patients could start funded GLP-1 treatment
1 March 2025[6] Funded liraglutide re-opened for high-risk T2D patients
March/April 2025[26] Medsafe approved Wegovy for weight loss in NZ
1 July 2025[25] Wegovy available on prescription at NZ pharmacies; dulaglutide fully restored for T2D
September 2025[17] Pharmac received Wegovy funding application (cardiovascular indication)
October 2025[17] Pharmac received Wegovy funding application (weight management)
December 2025[17] Pharmac advisory group provisionally recommended funding Wegovy — HIGH PRIORITY classification

Current NZ GLP-1 User Count

Segment Estimated Users Access Basis
Wegovy (weight loss) — dispensed since July 2025[25] 18,178 (Te Whatu Ora data) 100% private pay — no Pharmac subsidy
As % of NZ population (5.1M)[25] ~0.35% Private

NZ Drug Cost (Private Pay)

Drug Monthly Cost (NZD) USD Equivalent
Wegovy initial launch price[6] ~NZD $450 ~USD $270
Wegovy high-end range[26] NZD $450–$600 USD $270–$360

Pharmac Funding Scenario — Critical Market Catalyst

The December 2025 provisional recommendation by the Pharmac advisory group to fund Wegovy at HIGH PRIORITY status is the most significant near-term catalyst for NZ companion supplement TAM expansion. As of January 2026, the decision remains in price negotiation.[17] Criteria under review: BMI ≥27 with cardiovascular disease; BMI ≥30 with weight-related comorbidity.[6]

Funding Scenario Estimated Eligible Population Notes
Current (no funding, Wegovy private only)[25] ~18,000–35,000 active users Baseline for current TAM
BMI ≥30 + comorbidity criteria if funded[17] ~400,000–600,000 potentially eligible NZ adults Implies 33% obesity rate × 5.1M pop × comorbidity filter
5% initial uptake if funded[6] ~20,000–30,000 additional patients rapidly Conservative near-term scenario post-funding decision
Key finding: NZ's entire current weight-loss GLP-1 user base (18,178) is private-pay — smaller than a single mid-sized Australian city's user base. Pharmac funding approval would be a step-change event, potentially expanding the addressable population 10–20× within 24 months of listing.[17][25]

Section 6: Australia — Obesity Prevalence & Clinically Addressable Population

Source: Australian Institute of Health and Welfare (AIHW), drawing on 2022 ABS National Health Survey — official government data.[22]

Segment % of Adults Estimated Population
Overweight (BMI 25–29.9)[22] 34% ~6.9 million
Obese Class I/II (BMI 30–35)[22] ~27% ~5.5 million
Severely obese (BMI ≥35)[22] ~5% ~1.0 million
Total overweight + obese[22] 65.8% (2022) ~13.4 million
Waist circumference at disease risk[22] 67.9% ~13.8 million

Trend: Rising Severe Obesity

Metric 2007–08 2022–23 Change
Overweight or obese (adults)[22] 61.1% 64.8% +3.7pp
Obese (BMI ≥30)[22] 24.4% 31.1% +6.7pp
Severely obese (BMI ≥40)[22] 2.2% 4.6% +2.4pp (more than doubled)
Children 5–17 overweight/obese[22] 25% (2017–18) 28% (2022) +3pp

GLP-1 Clinical Eligibility vs. Current Penetration (AU)

Clinically eligible for GLP-1 treatment (BMI ≥30 + comorbidity, or BMI ≥35): approximately 3–5 million Australians. Current prescription penetration (~500,000 users) implies only 10–17% of eligible population is currently on GLP-1 medication — a large untapped pool even before PBS listing expands access.[22][14] Australia ranks 10th highest among 21 OECD countries for the proportion of overweight/obese people aged 15+.[22]

Section 7: New Zealand — Obesity Prevalence & Market Context

Metric Value
Adult obesity rate[26][6] ~33% (1 in 3 adults 15+ classified as obese)
OECD ranking[26] 3rd highest adult obesity rate in the OECD
NZ population (2025)[25] ~5.1 million
Estimated obese NZ adults[26] ~1.68 million
Children obesity rate[26] 1 in 8–10 classified as obese
Estimated annual health cost of excess weight[26] NZD $4–9 billion

The gap between the 1.68M obese adults and the 18,178 current Wegovy users (0.35% of total population, 1.1% of obese adults) illustrates the scale of latent demand. Even a modest 5% penetration of the obese adult population would represent ~84,000 GLP-1 users in NZ — a 4.6× expansion from today.[25][26][6]

Section 8: Australia — Broader Weight Management & Supplement Market (Triangulation Anchors)

Multiple independent market data points provide triangulation anchors for sizing the AU GLP-1 companion supplement segment as a fraction of the broader weight management and supplement ecosystem.

IBISWorld: AU Weight Loss Services (Broadest Weight Management Category)

Metric Value
2024 revenue[2] AUD $509.6 million
2025 projected[2] AUD $495.9 million
5-year CAGR (2019–2024)[2] -2.9% (structural decline)
Scope[2] Diet meal provision, online programs, personal counselling, diet shakes/bars/powders, non-medicinal supplements
Primary decline driver[2] Consumers shifting to GLP-1 medications and independent digital tools

IBISWorld: AU Online Vitamins & Supplements / Manufacturing

Category 2025 Revenue 5-Year CAGR
Online Vitamin & Supplement Sales[2] AUD $243.0 million +1.9%
Vitamin & Supplement Manufacturing[2] AUD $2.0 billion -0.4%

Grand View Research: AU Weight Loss Supplements (Primary TAM Anchor)

Metric Value
2024 revenue[8] USD $882.2 million (~AUD $1.35B)
2030 forecast[8] USD $1,972.5 million (~USD $2.0B)
CAGR (2025–2030)[8][16][24] 14.9% (also cited as 14.4% in one calculation window)
Australia's global share[8] 2.7% of global weight loss supplements market (2024)
Back-calculated global market[8] ~USD $32.7B (global weight loss supplements, broader than GLP-1 companion only)
Leading product form[8] Powder: 37.64% share

IMARC Group: AU Weight Management Market (Broadest Scope — Not Supplement-Only)

Metric Value
2024 market size[13] USD $15.76 billion
2033 projection[13] USD $27.18 billion
CAGR[13] 5.60%
Scope[13] Fitness equipment, gym memberships, diet programs, medications, supplements — NOT supplement-only

Precedence Research: AU Protein Supplements

Metric Value
2025 market size[27] USD $562.2 million
2034 projection[27] USD $1,027.7 million
CAGR[27] 6.72%
Whey protein price surge (Aug 2024–Dec 2025)[27] +52% (supply pressure + GLP-1 companion demand)
"GLP-1-friendly" claim growth on prebiotic supplements (2020–2024)[27] +78%

GLP-1 Functional Drinks Sub-Category (Global, No AU/NZ Breakdown)

Global GLP-1-friendly functional drinks are forecast to reach USD $3.48 billion by 2033 at a CAGR of 12.8% (2025–2033), with North America accounting for over 38% of global revenue (2024).[28] No AU/NZ-specific data is available in the published source.[28] The GLP-1 oral pill market is projected to grow from $3.2B (2025) to $34.3B (2031) at a 48.4% CAGR — a separate pharmaceutical category that would dramatically expand the companion supplement addressable base.[28]

Key finding: The AU weight loss supplements market (USD $882M, 2024) at a 14.9% CAGR is the most directly relevant triangulation anchor. If the GLP-1 companion supplement segment captures 15–25% of this category by 2030, it implies a segment of USD $296–$493M in AU alone — consistent with the bottom-up models in Section 13.[8]

Section 9: AU+NZ Combined Dietary Supplements Market

Grand View Research: AU+NZ Dietary Supplements (Primary Category)

Metric Value
2024 market size[12] USD $3.60 billion
2025 market size[12] USD $3.96 billion
2030 projection[12] USD $6.55 billion
CAGR (2025–2030)[12] 10.6%
Leading product segment[12] Vitamins: 29.4% share (2024)
Fastest-growing sub-segment[12] Proteins & amino acids: 13.9% CAGR (2025–2030)
Leading dosage form[12] Tablets: 31.6% share
Fastest-growing dosage form[12] Powders
Leading end user[12] Adults: 62.6% share
Fastest-growing channel[12] Online; prescribed supplements fastest-growing type
Liquid dietary supplements sub-market[31] USD $167.4 million (2024); 12.9% CAGR (2025–2030)

Grand View Research: AU+NZ Nutraceuticals (Broader — Including Functional Food & Beverage)

Metric Value
2024 market size[3] USD $11.51 billion
2033 projection[3] USD $26.10 billion
CAGR (2025–2033)[3] 9.5%
Leading revenue segment (2024)[31] Weight management & satiety — largest share

AU Dietary Supplements Market — Cross-Firm Size Comparison

Source Market Scope Year Size (USD unless noted) CAGR
IMARC Group[10] AU only 2025 $3.9B 7.02% (to 2034)
Mordor Intelligence[10] AU only 2025 $1.97B 8.33% (to 2030)
Grand View Research[12] AU+NZ combined 2024 $3.60B 10.6% (to 2030)
Expert Market Research[10] AU only (broader scope, AUD) 2025 AUD $8.82B 8.10% (to 2035)

Note: The 2× gap between IMARC ($3.9B) and Mordor ($1.97B) for the same market and year reflects fundamentally different category inclusions, not data quality differences. These figures are not reconciled and should not be averaged.[10]

Per-Capita Supplement Spend: AU vs. NZ

Market Vitamins & Minerals Per Capita (2024) 2029 Market Size Projection CAGR
Australia[20] USD $52.52 USD $1.91 billion 6.41%
New Zealand[21] USD $24.93 USD $178.60 million 6.33%
NZ vs. AU per-capita ratio[21][20] ~47% of AU level — —

Additional AU context: approximately 8 in 10 Australians supplement their diet with complementary and alternative medicines; vitamins, minerals, and supplements (VMS) account for >40% of the complementary and alternative medicines sector revenue; AU VMS exports exceeded 20 million kg in 2023 (worth >USD $480M).[20]

Section 10: GLP-1 Supplement Attach Rates & Clinical Demand Drivers

No single published attach rate figure exists for AU or NZ. The figures below are triangulated from multiple US-based consumer surveys and clinical studies, used as proxies for the AU/NZ market with appropriate discounting for the earlier-stage market context.[4][15][32]

Published Supplement Attach Rate Data Points

Category Attach Rate Source / Methodology
Protein shakes[4][19] ~30% Acosta Group consumer survey (US)
Protein powders[4] ~30% Acosta Group consumer survey (US)
Protein bars[4] ~29% Acosta Group consumer survey (US)
Probiotics[32] 13% (vs. 10% general population) Lumina Intelligence global survey
Physician-recommended protein formulation plans[15] 67.5% of nutrition plans include protein-based formulations FMI data, cited NutritionInsight
Sales via prescription-linked nutrition therapy[15] >60% of GLP-1 nutritional support market revenue (2025) FMI (global)

Working Attach Rate Assumptions for AU/NZ Bottom-Up Models

Scenario Total Supplement Attach Rate Rationale
Conservative[4] 25–30% Protein-only attach; early AU/NZ market; lower awareness
Mid-case[15] 30–40% Protein + fiber/probiotic; physician channel integration growing
Optimistic (2030)[15] 40–60% Mature market; clinical integration routine; PBS listing driving volume

Clinical Demand Drivers — Why Attach Rate Has a Structural Floor

Clinical Issue Prevalence / Magnitude Supplement Response
Muscle loss on GLP-1 therapy[4][19][27] 25–39% of total weight lost = lean mass over 36–72 weeks; 40–60% of weight loss may be muscle Protein (clinical guideline: 1.2–1.6 g/kg/day)
Nutritional deficiency at 6 months[19] 12.7% of GLP-1 users (vitamin D 7.5%; iron 1.6%; thiamine 0.02%); increases at 12 months Multivitamins; targeted micronutrient supplements
Reduced food intake[15][30] ~20% less food eaten on average; 31% less grocery spending Nutrient-dense supplements to compensate for dietary gap
GI side effects[32] Up to 50% report nausea, vomiting, diarrhea, constipation Fiber, probiotics, electrolytes, hydration products
Suboptimal vitamin K (population-wide)[19] ~70% of US population suboptimal (elevated further by GLP-1 diet restriction) K2 supplementation
Key finding: GLP-1-related product claim launches grew at a 124% CAGR over the past five years (Innova Market Insights), with North America capturing 83% of this growth to date.[15] AU/NZ are early in this curve — but the clinical demand drivers (muscle loss, nutritional deficiency, GI side effects) are identical to the US market.

GLP-1 Product Claim Growth Data

Product Type / Claim Growth Rate
GLP-1-related product claims on supplements (Innova Market Insights)[15] 124% CAGR (past five years)
"GLP-1-friendly" claim on prebiotic supplements (2020–2024)[27] +78% increase in use
Berberine ("Nature's Ozempic")[19] +21.6% YoY
Green supplements[19] +16.3% (year to October 2024)
Traditional fat burners[19] -10.5% YoY

See also: Consumer Behavior pillar for GLP-1 user preferences and willingness-to-pay data.

Section 11: ARPU & Spending Dynamics

AU/NZ Companion Supplement ARPU Benchmarks

Scenario Monthly ARPU (AUD) Basket Contents
Conservative[9] AUD $50–$75 Protein only, basic multi
Mid-case[30] AUD $100–$150 Protein + fiber + multivitamin
Premium[9] AUD $200–$300 Bundled program with coaching/testing

Per-Product Monthly Cost Breakdown (AU)

Product Monthly Cost (AUD)
Protein products[9] $30–$80
Vitamins[9] $20–$40
Fiber[9] $15–$30
Combined supplement basket[9][19] $50–$150 (blended)

GLP-1 Household Food & Supplement Spending Shifts

Category Change
Grocery spending within 6 months of GLP-1 adoption[30] -5.5%
Grocery spending — higher-income GLP-1 households[30] -8.6%
Grocery store spend vs. pre-medication[30] -31%
Fresh produce[30] +55%
Protein shakes / meal replacements / supplements / fitness[30] Significant increases (category rising)
Savory snacks, sweet/baked goods, soft drinks[30] Sharpest declines

Discontinuation Rate — Structural Market Dynamic

Approximately 50% of GLP-1 users discontinue within the first year (average across studies). After stopping, users regain an average of 0.4 kg/month and return to baseline weight within two years at 4× the rate vs. diet/activity alone.[4] Post-GLP-1 discontinuers represent a structurally distinct supplement customer segment with ongoing demand for supplement-based alternatives and weight-maintenance products — expanding the total addressable supplement opportunity beyond the active GLP-1 user count alone.[4]

See also: Consumer Behavior pillar for price sensitivity and willingness-to-pay modelling.

Section 12: Bottom-Up Sizing — New Zealand TAM / SAM / SOM

NZ Market Definition

NZ Current TAM (2025/2026 Baseline)

Model Users Attach Rate ARPU (NZD/mo) Annual TAM (NZD)
Conservative[6] 30,000 30% $65 ~$7.0M
Conservative-mid[9] 30,000 30% $75 ~$8.1M
Mid-case[6] 35,000 35% $100 ~$14.7M

NZ Per-Capita Cross-Check

NZ adult population (15+): ~4.1M. At Statista's USD $24.93 per-capita annual VMS spend, the entire NZ VMS market is approximately USD $102M/year.[21] The weight management sub-segment at 15–20% of total VMS implies a NZ weight management supplement market of USD $15–20M annually. GLP-1 companion as an early-stage sub-segment of that: under USD $10M currently — consistent with the bottom-up models above.[10][21]

Alternative NZ TAM — Population-Split from AU+NZ Combined

Combined AU+NZ dietary supplements = USD $3.60B (2024) (GVR).[12] NZ/AU population ratio: ~19.4%, but NZ per-capita VMS spend is ~47% of AU — adjusted NZ share is approximately USD $400–$550M in total dietary supplements (2024).[21][20] Weight management sub-segment (15–20%): NZ ~USD $60–110M. GLP-1 companion — further subset: USD $5–20M current TAM.[21][10]

NZ Post-Pharmac Funding Scenarios (Forward-Looking TAM)

Scenario Users Attach Rate ARPU (NZD/mo) Annual SAM (NZD)
2028 post-Pharmac funding (conservative)[6] 100,000 30% $65 ~$23.4M
2030 full penetration — low[6] 200,000 30% $75 ~$54.0M
2030 full penetration — high[6][21] 300,000 30% $75 ~$81.0M
2030 optimistic (BMI ≥27 funding criteria)[17] 400,000 35% $90 ~$151.2M
Key finding: At current private-pay penetration (18,178 Wegovy users), the NZ GLP-1 companion supplement TAM is small — NZD $7–15M annually. Pharmac funding approval is a non-linear catalyst: the 100,000-user scenario (moderate 2028 penetration) would generate a ~$23M NZD annual market, representing a 3–4× expansion in 24–36 months.[6][17]

Section 13: Bottom-Up Sizing — Australia TAM / SAM / SOM

AU Current TAM (2025 Baseline)

Model Active GLP-1 Users Attach Rate ARPU (AUD/mo) Annual TAM (AUD)
Conservative[5] 490,000 30% $75 ~$132M
Mid-case[9] 490,000 30% $125 ~$220M
Conservative-high[22] 500,000 35% $100 ~$210M
Mid-high[22] 500,000 40% $120 ~$288M

AU Weight Loss Supplement Cross-Check

AU weight loss supplements market (GVR, 2024): USD $882M (~AUD $1.35B).[8] At 30% attach rate and $75 AUD/month ARPU, the GLP-1 companion TAM estimate of $132–220M AUD represents approximately 10–16% of the total AU weight loss supplement market — consistent with an early-stage, high-growth sub-segment extraction from a broader category.[8][5]

AU 2030 TAM Projection

Model Projected Users Attach Rate ARPU (AUD/mo) Annual TAM (AUD)
Mid-case[5] 2,600,000 30% $75 ~$702M
Conservative[22] 2,500,000 40% $100 ~$1.2B
Optimistic[22] 2,500,000 60% $150 ~$2.7B

User projection basis: medRxiv authors project "almost 1 in 10 Australians" on a GLP-1 RA by 2030 — implying ~2.5–2.6 million active users (from a population of ~26M).[14][5] This projection assumes PBS listing expands access to lower-income, higher-BMI populations currently priced out of the private market.[29]

AU SAM — Private-Pay Weight Loss Sub-Segment (Highest-Value Cohort)

Private-pay weight loss GLP-1 users (180,018–239,725/month) are the highest-intent, highest-ARPU cohort.[14] At 40% attach and $150 AUD/month ARPU, this sub-segment alone generates a SAM of approximately $130–$170M AUD annually — the strategically optimal focus for a premium DTC companion supplement brand.

Key finding: The AU GLP-1 companion supplement market is estimated at AUD $132–288M annually in 2025 (conservative to mid-high case), scaling to AUD $700M–$2.7B by 2030 contingent on PBS listing expanding the user base to ~2.5M Australians. The 5× range in the 2030 estimate reflects genuine uncertainty in both the PBS listing timeline and the population attach rate in a government-subsidised context.[14][5][29]

Combined AU+NZ 2025 Market Summary

Market Current TAM (2025) 2030 TAM (Mid-Case)
Australia[5][9] AUD $132–$288M AUD $700M–$1.2B
New Zealand[6][9] NZD $7–$15M NZD $54–$81M (pre-/post-Pharmac funding)
Combined (indicative, AU-led)[22] AUD $140–$305M AUD $750M–$1.3B

Section 14: Emerging Product Categories, Innovation & Brand Activity

Top Supplement Categories for GLP-1 Users (Ranked by Clinical Priority)

Rank Category Clinical Rationale Supporting Data
1 Protein supplements[4][15][19] Muscle preservation; 25–39% lean mass loss on GLP-1 ~30% Acosta attach rate; FMI 43% product share; 1.2–1.6g/kg/day guideline
2 Fiber solutions[4][30] GI side effect management; satiety support 50% GI side effect rate; Vitamin Shoppe fiber SKU in core range
3 Hydration / electrolytes[15] Electrolyte replenishment from nausea/vomiting Industry clinician recommendations; emerging DTC SKU category
4 Multivitamins[19] Nutrient gap filling (12.7% new deficiency at 6 months) 12.7% clinical deficiency incidence; ~70% suboptimal vitamin K
5 Probiotics / microbiome[32] Gut health maintenance; GI side effect mitigation 13% attach rate (Lumina Intelligence); growing faster than general population
6 Green supplements[19] Micronutrient density; caloric restriction compensation +16.3% growth in year to October 2024 among GLP-1 segment

Global Brand Activity

Brand GLP-1 Companion Product Activity Launch Date
Herbalife[15] GLP-1 Nutrition Companion range — curated product combinations February 2024
Nestlé Health Science[15] glp-1nutrition.com platform; developing "companion products" June 2024
The Vitamin Shoppe[15] GLP-1-specific shelves; SKUs: meal-replacement powder, fiber, multivitamin, collagen protein 2024
Nature Made[15] GLP-1 Companion Health Pack (daily packets) 2024
GNC[15] Semaglutide Side Effect Support product line 2024

AU-Specific GLP-1 Companion Brands

Brand Category Notes
The Fast 800[27] AU-based; fiber + protein GLP-1 support bundles Established AU brand with GLP-1 support positioning
Replenza[27] DTC; glycemic control + lean mass preservation Emerging AU DTC brand with GLP-1-supportive marketing
Keptropy[27] DTC; post-meal tolerance AU-focused GLP-1 adjacent supplement brand
FullWell[27] DTC; GLP-1 supportive formulations AU-focused emerging brand

NZ-Specific GLP-1 Adjacent Brands

Brand Product Notes
Calocurb[3] Natural GLP-1 stimulant capsule featuring Amarasate® (patented hops extract) 15 years + $30M NZ Crown Research (Plant & Food Research) backing; available at calocurb.co.nz, nutriscript.co.nz (NZ & AU)
Naturecan NZ[3] GLP-1 Bundle: Berberine, Reducose™, Digest Gummies, Vegan Omega-3, high-quality protein International brand with NZ GLP-1 bundle positioning

OTC GLP-1 "support" supplements in NZ operate in a relatively new and partially unregulated space. A wave of supplements marketed as supportive of or replacing GLP-1 drug effects — containing nutrients and plant extracts claiming to slow gut emptying — has prompted a Dietitians NZ press release addressing GLP-1 companion nutritional considerations and 1News NZ coverage examining the evidence base (November 2024).[3]

Section 15: Data Quality Scorecard & Discrepancy Register

Source Credibility Ranking

Source Credibility Tier Key Limitations
AIHW (AU obesity data)[22] Tier 1 — Government primary 2022 survey; next update pending
medRxiv preprint (AU prescription volume)[14] Tier 2 — Academic, not peer-reviewed Preprint status; pharmaceutical sales data not individual-level
PBS.gov.au / PBAC (AU regulatory)[29] Tier 1 — Government primary Limited market-sizing content; authoritative for regulatory facts
Pharmac NZ (NZ regulatory)[17][6][25] Tier 1 — Government primary Three raw files from same URL; redundancy managed in consolidation
IBISWorld (AU weight loss services)[2] Tier 2 — Established commercial Industry category definitions may not map precisely to GLP-1 sub-segment
Grand View Research (multiple reports)[8][12][3] Tier 2–3 — Commercial market research Methodology paywalled; some internal CAGR discrepancies (14.4% vs 14.9%)
Statista (per-capita spend)[20][21] Tier 2 — Established commercial VMS scope only; not GLP-1-specific
NutraIngredients / NutritionInsight[19][15][28] Tier 3 — Trade press citing primary Secondary sources; Acosta/Lumina/Innova data require primary verification
Future Market Insights[1][11][23] Tier 4 — Lower-credibility commercial No methodology transparency; syndicated via OpenPR press releases
wifitalents.com (credibility analysis)[18] Tier 4 — Blog aggregator No primary research; useful only as a compilation of other sources' figures

Material Discrepancies Register

Discrepancy Source A Source B Resolution
AU dietary supplements market size[10] IMARC: USD $3.9B (2025) Mordor: USD $1.97B (2025) ~2× gap reflects different category scope; not reconciled
AU weight loss supplements CAGR[8] GVR: 14.9% (2025–2030) GVR same report: 14.4% (2024–2030) Different base year windows within same report; use 14.9% as primary figure
Global $4.2B figure origin[18][7] Trade media: widely cited as $4.2B (2025) FMI published: $4.1B (2025) Probable rounding of FMI figure; no confirmed primary source for $4.2B
Global "$8.4B by 2030" figure[7][18] Trade media: $8.4B by 2030 FMI math: $4.1B × (1.122)^5 ≈ $7.3B by 2030 Confirmed inconsistency — $8.4B implies ~15% CAGR vs. FMI's stated 12.2%
GLP-1 companion market contribution[11] FMI: "3–5% of GLP-1 pharmaceutical ecosystem" Morgan Stanley: GLP-1 drug market $190B by 2035 3–5% of $190B pharmaceutical = $5.7–9.5B supplement market (2035) — broadly consistent with FMI's $13B 2035 projection if scope is wider

Data Gaps

Sources

  1. GLP-1 Nutritional Support Market Size & Share 2025-2035 — Future Market Insights (retrieved 2026-05-05)
  2. Weight Loss Services in Australia Industry Analysis 2024 — IBISWorld (retrieved 2026-05-05)
  3. Australia & New Zealand Nutraceuticals Market Report 2033 — Grand View Research (retrieved 2026-05-05)
  4. Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug — KFF (retrieved 2026-05-05)
  5. The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025 — medRxiv (retrieved 2026-05-05)
  6. Wegovy and Mounjaro for weight loss not funded — Pharmac NZ Government (retrieved 2026-05-05)
  7. GLP-1 Nutritional Support Market Forecast at 12.2% CAGR Through 2035 — OpenPR / Future Market Insights (retrieved 2026-05-05)
  8. Australia Weight Loss Supplements Market Size & Outlook, 2030 — Grand View Research (retrieved 2026-05-05)
  9. How are GLP-1 drugs impacting spending on food and dietary supplements? — AgFunder News (retrieved 2026-05-05)
  10. Australia Dietary Supplements Market Size, Growth | 2034 — IMARC Group (retrieved 2026-05-05)
  11. GLP-1 Nutritional Support Market Size & Share 2025-2035 — Future Market Insights (retrieved 2026-05-05)
  12. Australia & New Zealand Dietary Supplements Market Size & Share 2025-2030 — Grand View Research (retrieved 2026-05-05)
  13. Australia Weight Management Market Size, Share & Trends 2025-2033 — IMARC Group (retrieved 2026-05-05)
  14. The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025 — medRxiv preprint (retrieved 2026-05-05)
  15. How the supplement industry is bridging Ozempic's nutrition gaps — NutritionInsight (retrieved 2026-05-05)
  16. Australia Weight Loss Supplements Market Size & Outlook 2030 — Grand View Research (retrieved 2026-05-05)
  17. Wegovy and Mounjaro for weight loss not funded — PHARMAC NZ Government (retrieved 2026-05-05)
  18. GLP-1 Supplement Industry Statistics 2026 — Source Credibility Analysis (retrieved 2026-05-05)
  19. How are GLP-1 drugs altering consumer demand for supplements? — NutraIngredients 2026 (retrieved 2026-05-05)
  20. Vitamins, minerals, and supplements market in Australia — Statista (retrieved 2026-05-05)
  21. Vitamins & Minerals — New Zealand | Statista Market Forecast (retrieved 2026-05-05)
  22. Overweight and obesity Summary — Australian Institute of Health and Welfare (AIHW) (retrieved 2026-05-05)
  23. GLP-1 Nutritional Support Market Size & Share 2025-2035 — Future Market Insights (retrieved 2026-05-05)
  24. Australia Weight Loss Supplements Market Size & Outlook, 2030 — Grand View Research (retrieved 2026-05-05)
  25. Wegovy and Mounjaro for weight loss not funded — Pharmac (NZ Government) (retrieved 2026-05-05)
  26. Everything you need to know about Ozempic and Wegovy in New Zealand — The Spinoff (retrieved 2026-05-05)
  27. Australia GLP-1 Receptor Agonist Market Size 2025 to 2034 — Precedence Research (retrieved 2026-05-05)
  28. GLP-1 functional drinks market set for rapid global growth — NutraIngredients (retrieved 2026-05-05)
  29. Pharmaceutical Benefits Advisory Committee (PBAC) advice on equitable access to GLP-1 obesity treatments — PBS.gov.au (Australian Government) (retrieved 2026-05-05)
  30. How are GLP-1 drugs impacting spending on food and dietary supplements? — AgFunder News (retrieved 2026-05-05)
  31. Australia & New Zealand Dietary Supplements Market Report, 2030 — Grand View Research (retrieved 2026-05-05)
  32. Companion product opportunities: 5 charts explaining the GLP-1 consumer — NutraIngredients (retrieved 2026-05-05)

Home